Dechra Pharmaceuticals Stock Price, News & Analysis (LON:DPH)

GBX 1,985 -2.00 (-0.10 %)
(As of 12/15/2017 04:00 PM ET)
Previous CloseGBX 1,985
Today's RangeGBX 1,984 - GBX 2,006
52-Week RangeGBX 1,256 - GBX 2,272
Volume135,066 shs
Average Volume133,040 shs
Market Capitalization£1.89 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A

About Dechra Pharmaceuticals (LON:DPH)

Dechra Pharmaceuticals logoDechra Pharmaceuticals PLC is engaged in veterinary pharmaceuticals and related products business. The Company is engaged in development, manufacture and marketing of products for veterinarians. Its segments include European Pharmaceuticals, North American (NA) Pharmaceuticals and Pharmaceuticals Research and Development. The European Pharmaceuticals Segment includes Dechra Veterinary Products Europe, Genera and Dechra Pharmaceuticals Manufacturing. It manufactures and markets Companion Animal, Equine and Food producing Animal Products. It includes third party manufacturing and other non-core activities sales. The NA Pharmaceuticals Segment consists of Dechra Veterinary Products US, Putney, Dechra Veterinary Products Canada, and Dechra-Brovel that sell Companion Animal and Equine Products into those territories. The Pharmaceuticals Research and Development Segment includes its pharmaceutical research and development activities. Its offerings include Osphos and Vetoryl.

Receive DPH News and Ratings via Email

Sign-up to receive the latest news and ratings for DPH and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Veterinary Drugs
Sub-IndustryN/A
SectorVeterinary Drugs
SymbolLON:DPH
CUSIPN/A
Phone+44-1606-814730

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

Trailing EPSGBX 0.28
Net IncomeN/A
Net Margins7.15%
Return on Equity9.08%
Return on Assets4.25%

Miscellaneous

EmployeesN/A
Outstanding Shares93,420,000

Dechra Pharmaceuticals (LON:DPH) Frequently Asked Questions

What is Dechra Pharmaceuticals' stock symbol?

Dechra Pharmaceuticals trades on the London Stock Exchange (LON) under the ticker symbol "DPH."

How often does Dechra Pharmaceuticals pay dividends? What is the dividend yield for Dechra Pharmaceuticals?

Dechra Pharmaceuticals declared a dividend on Monday, September 4th. Shareholders of record on Thursday, October 26th will be paid a dividend of GBX 15.33 per share on Friday, November 17th. This represents a yield of 0.74%. The ex-dividend date is Thursday, October 26th. This is a boost from Dechra Pharmaceuticals's previous dividend of $6.11. The official announcement can be viewed at this link. View Dechra Pharmaceuticals' Dividend History.

Where is Dechra Pharmaceuticals' stock going? Where will Dechra Pharmaceuticals' stock price be in 2017?

6 Wall Street analysts have issued twelve-month price objectives for Dechra Pharmaceuticals' shares. Their predictions range from GBX 1,550 to GBX 1,890. On average, they expect Dechra Pharmaceuticals' stock price to reach GBX 1,784 in the next twelve months. View Analyst Ratings for Dechra Pharmaceuticals.

Who are some of Dechra Pharmaceuticals' key competitors?

Who are Dechra Pharmaceuticals' key executives?

Dechra Pharmaceuticals' management team includes the folowing people:

  • Ian David Page, Chief Executive Officer, Executive Director
  • Richard Cotton, Chief Financial Officer, Executive Director (Age 55)
  • Mike Eldred, President, North America
  • Anthony Gerard Griffin, Managing Director - Dechra Veterinary Products Europe, Executive Director (Age 51)
  • Katy Clough, Group HR Director
  • Giles Coley, Group Director - Veterinary Products International (Age 55)
  • Susan Longhofer, Regulatory Affairs and Business Development Group Director
  • Anthony Lucas, Group Product Development Director
  • Allen Mellor, Group IT Director
  • Greig Rooney, Group Manufacturing and Supply Director

How do I buy Dechra Pharmaceuticals stock?

Shares of Dechra Pharmaceuticals and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Dechra Pharmaceuticals' stock price today?

One share of Dechra Pharmaceuticals stock can currently be purchased for approximately GBX 1,985.

How big of a company is Dechra Pharmaceuticals?

Dechra Pharmaceuticals has a market capitalization of £1.89 billion.

How can I contact Dechra Pharmaceuticals?

Dechra Pharmaceuticals' mailing address is 24 Cheshire Business Park Cheshire Avenue, NORTHWICH, CW9 7UA, United Kingdom. The company can be reached via phone at +44-1606-814730.


MarketBeat Community Rating for Dechra Pharmaceuticals (DPH)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  174 (Vote Outperform)
Underperform Votes:  206 (Vote Underperform)
Total Votes:  380
MarketBeat's community ratings are surveys of what our community members think about Dechra Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Dechra Pharmaceuticals (LON:DPH) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.572.572.572.57
Ratings Breakdown: 0 Sell Rating(s)
3 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
3 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
3 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
3 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: GBX 1,692GBX 1,692GBX 1,692GBX 1,576.43

Dechra Pharmaceuticals (LON:DPH) Consensus Price Target History

Price Target History for Dechra Pharmaceuticals (LON:DPH)

Dechra Pharmaceuticals (LON:DPH) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetDetails
9/5/2017Jefferies GroupBoost Price TargetHoldGBX 1,565 -> GBX 1,868View Rating Details
7/11/2017Stifel NicolausReiterated RatingHoldGBX 1,550View Rating Details
7/6/2017InvestecReiterated RatingBuyGBX 1,840View Rating Details
7/6/2017N+1 SingerReiterated RatingBuyGBX 1,666View Rating Details
7/6/2017Numis SecuritiesReiterated RatingAddGBX 1,890View Rating Details
4/20/2017Panmure GordonReiterated RatingUnder ReviewView Rating Details
3/14/2017Royal Bank of CanadaBoost Price TargetOutperformGBX 1,630 -> GBX 1,890View Rating Details
2/24/2017FinnCapReiterated RatingUnder ReviewView Rating Details
(Data available from 12/15/2015 forward)

Earnings

Earnings History for Dechra Pharmaceuticals (LON:DPH)


No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Dechra Pharmaceuticals (LON:DPH) Earnings Estimates

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dechra Pharmaceuticals (LON:DPH) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
9/4/2017GBX 15.330.74%10/26/201710/26/201711/17/2017
2/27/2017GBX 6.110.38%3/9/20173/9/20174/7/2017
9/5/2016GBX 12.910.92%10/27/201610/27/201611/18/2016
2/22/2016GBX 5.550.47%3/10/20163/10/20164/6/2016
9/7/2015GBX 11.821.26%10/29/201510/29/201511/20/2015
9/8/2014GBX 10.651.4%11/6/201411/6/201411/21/2014
2/25/2014GBX 4.750.68%3/12/20143/12/20144/8/2014
(Data available from 1/1/2013 forward)

Insider Trades

Dechra Pharmaceuticals (LON DPH) Insider Trading and Institutional Ownership History

Insider Trades by Quarter for Dechra Pharmaceuticals (LON:DPH)

Dechra Pharmaceuticals (LON DPH) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/19/2017Ian PageInsiderSell54,910GBX 2,024£1,111,378.40
6/21/2017Ian PageInsiderSell134,500GBX 1,927£2,591,815
5/2/2017Ian PageInsiderSell1,630GBX 1,715£27,954.50
3/21/2017Tony GriffinInsiderSell3,500GBX 1,676£58,660
11/30/2016Tony GriffinInsiderSell17,133GBX 1,292£221,358.36
6/3/2016Rice,TonyInsiderBuy20,000GBX 1,141£228,200
3/21/2016Nesmes,Anne-FrancoiseInsiderSell3,100GBX 1,208£37,448
9/9/2015Nesmes,Anne-FrancoiseÂInsiderSell18,319GBX 940£172,198.60
(Data available from 1/1/2013 forward)

Headlines

Dechra Pharmaceuticals (LON DPH) News Headlines

Source:
DateHeadline
Dechra Pharmaceuticals plc (DPH) Given Average Rating of "Buy" by AnalystsDechra Pharmaceuticals plc (DPH) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - December 7 at 11:52 AM
Dechra Pharmaceuticals PLC – Value Analysis (LONDON:DPH) : December 6, 2017Dechra Pharmaceuticals PLC – Value Analysis (LONDON:DPH) : December 6, 2017
finance.yahoo.com - December 6 at 5:34 PM
Dechra Pharmaceuticals PLC breached its 50 day moving average in a Bearish Manner : DPH-GB : December 5, 2017Dechra Pharmaceuticals PLC breached its 50 day moving average in a Bearish Manner : DPH-GB : December 5, 2017
finance.yahoo.com - December 5 at 9:55 AM
Dechra Pharmaceuticals plc (DPH) Receives Average Rating of "Buy" from AnalystsDechra Pharmaceuticals plc (DPH) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - November 12 at 11:40 AM
ETFs with exposure to Dechra Pharmaceuticals PLC : October 26, 2017ETFs with exposure to Dechra Pharmaceuticals PLC : October 26, 2017
finance.yahoo.com - October 26 at 1:53 PM
Dechra Pharmaceuticals plc (DPH) Declares Dividend Increase - GBX 15.33 Per ShareDechra Pharmaceuticals plc (DPH) Declares Dividend Increase - GBX 15.33 Per Share
www.americanbankingnews.com - October 21 at 9:10 AM
Dechra Pharmaceuticals plc (DPH) Receives Average Recommendation of "Buy" from AnalystsDechra Pharmaceuticals plc (DPH) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - October 18 at 2:50 PM
Dechra Pharmaceuticals plc (DPH) Given Consensus Recommendation of "Buy" by BrokeragesDechra Pharmaceuticals plc (DPH) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - September 23 at 12:40 PM
Dechra Pharmaceuticals plc (DPH) Insider Ian Page Sells 54,910 SharesDechra Pharmaceuticals plc (DPH) Insider Ian Page Sells 54,910 Shares
www.americanbankingnews.com - September 20 at 1:16 PM
ETFs with exposure to Dechra Pharmaceuticals PLC : September 15, 2017ETFs with exposure to Dechra Pharmaceuticals PLC : September 15, 2017
finance.yahoo.com - September 15 at 6:26 PM
Dechra Pharmaceuticals PLC :DPH-GB: Earnings Analysis: 2017 By the Numbers : September 14, 2017Dechra Pharmaceuticals PLC :DPH-GB: Earnings Analysis: 2017 By the Numbers : September 14, 2017
finance.yahoo.com - September 14 at 12:19 AM
What Is Dechra Pharmaceuticals plc’s (LSE:DPH) Share Price Doing?What Is Dechra Pharmaceuticals plc’s (LSE:DPH) Share Price Doing?
finance.yahoo.com - September 11 at 3:43 PM
[$$] Dechra sales boosted by acquisitions and new drugs[$$] Dechra sales boosted by acquisitions and new drugs
finance.yahoo.com - September 4 at 10:43 PM
Dechra Pharmaceuticals PLC - 20 Years of Strategic GrowthDechra Pharmaceuticals PLC - 20 Years of Strategic Growth
finance.yahoo.com - September 4 at 5:40 PM
Edited Transcript of DPH.L earnings conference call or presentation 4-Sep-17 9:30am GMTEdited Transcript of DPH.L earnings conference call or presentation 4-Sep-17 9:30am GMT
finance.yahoo.com - September 4 at 5:40 PM
Dechra FY Pre-tax Profit Rises; Says Current Trading In Line With Board ViewDechra FY Pre-tax Profit Rises; Says Current Trading In Line With Board View
www.rttnews.com - September 4 at 3:30 AM
Dechra Pharmaceuticals plc (DPH) Scheduled to Post Quarterly Earnings on MondayDechra Pharmaceuticals plc (DPH) Scheduled to Post Quarterly Earnings on Monday
www.americanbankingnews.com - August 28 at 1:46 AM
Dechra Pharmaceuticals plc (DPH) Receives Average Rating of "Buy" from BrokeragesDechra Pharmaceuticals plc (DPH) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - July 10 at 12:49 PM
Dechra Pharmaceuticals plcs (LON:DPH) Add Rating Reaffirmed at Numis Securities LtdDechra Pharmaceuticals plc's (LON:DPH) Add Rating Reaffirmed at Numis Securities Ltd
www.americanbankingnews.com - July 9 at 9:25 AM
Dechra Pharmaceuticals plc (LON:DPH) Receives Buy Rating from N+1 SingerDechra Pharmaceuticals plc (LON:DPH) Receives Buy Rating from N+1 Singer
www.americanbankingnews.com - July 9 at 7:30 AM
Dechra Pharmaceuticals plc (LON:DPH) Earns Buy Rating from InvestecDechra Pharmaceuticals plc (LON:DPH) Earns Buy Rating from Investec
www.americanbankingnews.com - July 6 at 9:02 AM
Dechra Pharma Says FY Trading In Line With Its ViewDechra Pharma Says FY Trading In Line With Its View
www.rttnews.com - July 6 at 4:47 AM
Dechra® Pharmaceuticals PLC (LSE symbol DPH) Releases its 2017 Half-yearly Financial Report - PR Newswire (press release)Dechra® Pharmaceuticals PLC (LSE symbol DPH) Releases its 2017 Half-yearly Financial Report - PR Newswire (press release)
www.prnewswire.com - February 28 at 8:12 AM
Half Year 2017 Dechra Pharmaceuticals PLC Earnings Release - Before Market OpenHalf Year 2017 Dechra Pharmaceuticals PLC Earnings Release - Before Market Open
biz.yahoo.com - February 27 at 7:36 PM
Why I’m avoiding these exciting growth shares right nowWhy I’m avoiding these exciting growth shares right now
uk.finance.yahoo.com - February 16 at 2:55 PM
Should you make room for Pets At Home Group plc after todays update? - Yahoo Finance UKShould you make room for Pets At Home Group plc after today's update? - Yahoo Finance UK
uk.finance.yahoo.com - January 19 at 11:07 PM
Should you make room for Pets At Home Group plc after today’s update?Should you make room for Pets At Home Group plc after today’s update?
uk.finance.yahoo.com - January 19 at 6:06 PM
Does this pharmas 56% sales growth make it a better buy than GlaxoSmithKline plc? - Yahoo Finance UKDoes this pharma's 56% sales growth make it a better buy than GlaxoSmithKline plc? - Yahoo Finance UK
uk.finance.yahoo.com - January 17 at 8:22 AM
Does this pharma’s 56% sales growth make it a better buy than GlaxoSmithKline plc?Does this pharma’s 56% sales growth make it a better buy than GlaxoSmithKline plc?
uk.finance.yahoo.com - January 17 at 8:22 AM
Could these top-performing stocks be about to collapse?Could these top-performing stocks be about to collapse?
uk.finance.yahoo.com - November 7 at 5:46 AM
Are These Pharma Fizzers Hot Buys After Todays News?Are These Pharma Fizzers 'Hot Buys' After Today's News?
www.forbes.com - October 21 at 4:44 PM

SEC Filings

Dechra Pharmaceuticals (LON:DPH) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Social activity is not available for this stock.

Financials

Financials are not available for this stock.

Chart

Dechra Pharmaceuticals (LON DPH) Stock Chart for Friday, December, 15, 2017

Loading chart…

This page was last updated on 12/15/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.